ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 0691 • ACR Convergence 2024

    Predictors of Response and Long-term Efficacy and Safety of Nintedanib in Systemic Sclerosis-Interstitial Lung Disease: Data from an Italian Multicentre Study

    Corrado Campochiaro1, Giacomo De Luca2, Maria-Grazia Lazzaroni3, Giuseppe Armentaro4, Amelia Spinella5, Chiara Bellocchi6, Barbara Ruaro7, Anna Stanziola8, Devis Benfaremo9, Enrico De Lorenzis10, Beatrice Moccaldi11, Francesco Bonomi12, Lorenzo Bianchessi13, Florenzo Iannone14, Fabio Cacciapaglia15, Lorenzo Beretta16, Serena Guiducci17, Veronica Codullo18, Silvia Laura Bosello19, Giovanna Cuomo20, Elisabetta Zanatta11, Nicoletta Del Papa4, Paolo Airò3, paola Confalonieri7, Gianluca Moroncini9, Dilia Giuggioli5, Lorenzo Dagna21 and Marco Matucci-Cerinic22, 1IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, 2Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, 3Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 4Scleroderma Clinic, Dip. Reumatologia, ASST G. Pini-CTO, Milan, Italy, 5Scleroderma Unit, University of Modena and Reggio Emilia, Modena, Italy, 6Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, 7Unit of Respiratory Medicine, University of Trieste, Trieste, Italy, 8Unit of Respiratory Medicine, Federico II University Hospital, Napoli, Italy, 9Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Marche University Hospital, Ancona, Italy, 10Catholic University of the Sacred Heart, Roma, Rome, Italy, 11Unit of Rheumatology, Padova University, Padova, Italy, 12Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, 13Unit of Rheumatology, San Matteo Hospital, Pavia, 14Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, 15Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, 16Scleroderma Unit, Fondazione IRCCS Ca' Granda, University of Milan, Milan, Italy, 17Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 18Unit of Rheumatology, San Matteo Hospital, Pavia, Italy, 19Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 20Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, 21IRCCS San Raffaele Scientific Institute, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milano, Italy, Milan, Italy, 22University San Raffaele Milano, Milano, Milan, Italy

    Background/Purpose: The SENSCIS trial and the SENSCIS-ON study have shown that nintedanib (NTD) reduces the rate of decline in Interstitial Lung Disease (ILD) in Systemic…
  • Abstract Number: 0955 • ACR Convergence 2024

    Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis

    Goncalo Boleto1, Anne Cauvet2, James Rose3, Lih-Yun Hsu3, Richard A. Miller3 and Yannick Allanore4, 1Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, 2Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, 3Corvus Pharmaceuticals, 863 Mitten Road, Burlingame, Burlingame, CA, 4Université Paris Cité, Paris, France

    Background/Purpose: T cells abnormal activation plays a pivotal role in the early inflammatory stages of systemic sclerosis (SSc). Compelling evidence supports that SSc has a…
  • Abstract Number: 1170 • ACR Convergence 2024

    Computer Aided Lung Informatics, HRCT and PFT in Patients with Interstitial Lung Disease in Idiopathic Inflammatory Myopathies

    Sonali Narain1, Kourosh Shargani2, Ivana Ilic3, Irvind Buttar4 and Galina Marder5, 1Northwell Health, Great Neck, NY, 2Northwell, Manhasset, NY, 3Northwell, Brooklyn, NY, 4Northwell Health/ Lenox Hill Hospital, Dix Hills, NY, 5Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY

    Background/Purpose: Evaluation of Interstitial Lung Disease (ILD) progression relies on high resolution computed tomography (HRCT) and pulmonary function test (PFT). As we previously reported in our Idiopathic…
  • Abstract Number: 1691 • ACR Convergence 2024

    Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease

    Elizabeth Volkmann1, Holly Wilhalme2, Donald Tashkin2, Grace Kim2, Jonathan Goldin2, Alana Haussmann2, Masataka Kuwana3, Michael Roth2 and Shervin Assassi4, 1University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles, 2UCLA, Los Angeles, 3Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 4UTHealth Houston Division of Rheumatology, Houston, TX

    Background/Purpose: Despite the expanding treatment landscape for systemic sclerosis-associated interstitial lung disease (SSc-ILD), the lack of early and valid treatment response biomarkers (measurable in the…
  • Abstract Number: 2208 • ACR Convergence 2024

    Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry

    Aparna Swaminathan1, Jeremy Weber2, Jamie Todd3, Scott Palmer3, Megan Neely3, Peide Li4 and Ann Chauffe5, and on behalf of the ILD-PRO Registry investigators, 1Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, NC, 2Duke Clinical Research Institute, Durham, NC, 3Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, 4Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, 5Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT

    Background/Purpose: The ILD-PRO Registry is a multicenter US registry of patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We…
  • Abstract Number: 2474 • ACR Convergence 2024

    High-throughput Screening Identifies Specific Molecular Markers for ILD in Patients with Rheumatic Diseases

    Anna-Maria Hoffmann-Vold1, Vyacheslav Palchevskiy2, Phuong Phuong Diep3, Henriette Didriksen1, Mona Lovise Talaro Ramsli1, Jin Zhou4, Shahrzad Lari4, Elena Pachera5, Michael T Durheim1, Øyvind Molberg6, Oliver Distler7, S. Samuel Weigt2 and John A Belperio4, 1Oslo University Hospital, Oslo, Norway, 2University of California Los Angeles, Los Angeles, CA, 3Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, 4University of California Los Angeles, Los Angeles, 5University Hospital Zurich, Zurich, Switzerland, 6Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 7Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: Molecular expression patterns of lung tissue across rheumatic musculoskeletal diseases (RMDs) have not been extensively studied. Lung sampling is invasive and not always practical…
  • Abstract Number: 0339 • ACR Convergence 2024

    Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study

    Anjana Srikumar, Keon Niknejad, Maria Kaltchenko and Jun Kang, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease associated with higher rates of hospitalization, longer lengths of stay, higher mean hospitalization costs, and increased inpatient…
  • Abstract Number: 0692 • ACR Convergence 2024

    Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis

    Miriam Retuerto Guerrero1, Clara Moriano2, cristiana sieiro santos3, Laura Sierra Herranz4, Javier Juan Garcia4, Ivan Castellvi Barranco5 and elvira Diez álvarez4, 1Complejo Asistencial Universitario de León, Leon, Spain, 2Hospital León, LEON, Spain, 3Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, 4Complejo Asistencial Universitario de Leon, Leon, 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and is one of the leading causes of morbidity and mortality. Recently,…
  • Abstract Number: 0956 • ACR Convergence 2024

    Secreted Frizzled-Related Protein 2 (sFRP2) Regulates Wnt Signaling to Affect Mesenchymal Transition of Lung Epithelial Cells Participates in Interstitial Lung Disease

    Yinlan Wu1, Yanhong Li2 and Yi Liu3, 1West China Hospital of Sichuan University, Chengdu, Sichuan, China, 2West China School of Medicine and West China Hospital, Sichuan University, Cheng Du, Sichuan, China, 3West China Hospital, Sichuan University, Chengdu, China (People's Republic)

    Background/Purpose: Investigation of Transcriptional Changes in Interstitial Lung Disease (ILD) and Exploration of Functional Effects of Differential Genes and Expressed Proteins in the Development of…
  • Abstract Number: 1324 • ACR Convergence 2024

    Rheumatoid Arthritis Associated Interstitial Lung Disease – Patient Perceptions and Recommendations

    Shirish Dubey1, Abhinav Peddasomayajula2, Damodar Makkuni3, Anupama Nandagudi4, Win Win Maw5 and Gouri M Koduri6, 1Oxford University Hospitals NHS FT, Oxford, United Kingdom, 2Mid and South Essex NHS Foundation Trust, Southend, England, United Kingdom, 3James Paget University Hospital NSH FT, Great Yarmouth, United Kingdom, 4MSEFT, Basildon, United Kingdom, 5Mid and South Essex NHS Foundation Trust, Chelmsford, England, United Kingdom, 6Southend Univeristy Hospitals NHS Trust, Essex, United Kingdom

    Background/Purpose: Interstitial lung disease (ILD) is one of the complications of rheumatoid arthritis (RA) and has significant impact on morbidity and mortality. RA significantly reduces…
  • Abstract Number: 1692 • ACR Convergence 2024

    Single Cell RNA-seq Identifies Circulating Double-negative-2 B-cell Population Associated with Progressive Scleroderma Interstitial Lung Disease

    Trinitee Oliver1, Kim Taylor2, Ye Cao3, Takanori Sasaki4, Deepak Rao5, Nunzio Bottini6, Francesco Boin6 and Richard Ainsworth6, 1Cedars-Sinai Medical Center, Hawthorne, CA, 2University of California, San Francisco, CA, 3Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: B-cell subsets display aberrant function in systemic sclerosis (SSc) pathogenesis and infiltrate the lungs of SSc patients with interstitial lung disease (ILD). B-cells relevance…
  • Abstract Number: 2222 • ACR Convergence 2024

    Primary Lung Involvement in Early Rheumatoid Arthritis

    Martí Aguilar Coll1, Javier Narvaez-García2, Alejandro Robles Pérez1, Patricio Luburich1, Vanesa Vicens-Zygmunt3, Gualadalupe Bermudo3, Santiago Bolivar1, Pol Maymó3, Judith Palacios1, Monserrat Roig Kim2, Laia De Daniel2, Maria Molina-Molina3 and Joan Miquel Nolla1, 1Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain, 2Hospital Universitario de Bellvitge, Barcelona, Spain, 3Hospital Universitario de Bellvitge., Barcelona, Spain

    Background/Purpose: Since there is broad variability within the studies investigating this issue, it is not possible nowadays to reliably establish prevalence and incidence of rheumatoid…
  • Abstract Number: 2475 • ACR Convergence 2024

    The Critical Role of Annual HRCT in Identifying ILD Progression and Assessing Outcome in SSc

    Anna-Maria Hoffmann-Vold1, Simon Beyeler2, Liubov Petelytska3, Håvard Fretheim1, Trond Mogens Aaløkken4, Mike Becker5, Hilde Jenssen Bjørkekjær6, Cathrine Brunborgg1, Cosimo Bruni7, Christian Clarenbach8, Phuong Phuong Diep9, Rucsandra Dobrota7, Michael T Durheim1, Muriel Elhai10, Thomas Frauenfelder8, Suzana Jordan7, Emily Langballe11, Øyvind Midtvedt12, Carina Mihai7, Adela Sarbu8, Marco Sprecher8, Øyvind Molberg13 and Oliver Distler14, 1Oslo University Hospital, Oslo, Norway, 2University Hospital Zurich, Zürich, Zurich, Switzerland, 3University Hospital Zurich, Zurich, Switzerland, 4Medicine, Oslo, Norway, Oslo, Norway, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 6Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Kristiansand, Norway, 7University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8University Hospital Zurich, Zurich, Zurich, Switzerland, 9Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, 10University Hospital zurich, Zürich, Switzerland, 11Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 12Oslo University Hospital, Oslo, Oslo, Norway, 13Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 14Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc). Monitoring with lung function testing every 3–6 months for…
  • Abstract Number: 0340 • ACR Convergence 2024

    Progressive Pulmonary Fibrosis Predicts Mortality in Myositis-Associated Interstitial Lung Disease

    Yu-Wan Liao1, Ming-Cheng Liu1, Pin-Kuei Fu1 and Wen-Nan Huang2, and Integrated Care Center of Interstitial Lung Disease, 1Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 2Taichung Veterans General Hospital, Taichung, Taiwan, Taichung, Taiwan (Republic of China)

    Background/Purpose: Myositis-associated interstitial lung disease (MA-ILD) is a complex condition with a variable prognosis and diverse clinical manifestations. The 2022 ATS/ERS/JRS/ALAT criteria for PPF provide…
  • Abstract Number: 0781 • ACR Convergence 2024

    An Expanded Cytotoxic CD8 T Cell Population Regulated by CD155-CD226 in SSc-ILD

    Takanori Sasaki1, Ye Cao2, Kathryne Marks3, Richard Ainsworth4, Kim Taylor5, Nunzio Bottini4, Mehreen Elahee6, Mari Kamiya3, Edy Kim6, Francesco Boin4 and Deepak Rao7, 1Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Cedars-Sinai Medical Center, Los Angeles, CA, 5University of California, San Francisco, CA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify circulating immune cells associated…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 39
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology